Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-562-7 | CAS number: 108-22-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The No Observed Adverse Effect Concentration (NOAEC) for systemic toxicity under the condition of a 28 days inhalative study was 2075 mg/m3 (500 ppm). The NOAEC for hyperplasia of nasal transitional and degeneration of olfactory epithelium was 830 mg/m3(200 ppm). A NOAEC for slight irritancy leading to nasal epithelial inflammatory cell infiltration in some ofthe animals could not be established.
Key value for chemical safety assessment
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEC
- 830 mg/m³
Additional information
Five male and five female Wistar rats per test group were whole body exposed to dynamic at-mospheres of 2-Acetoxypropene (Essigsaeureisopropenylester) vapours for 6 hours per working day for about 28 days (20 exposures). The target concentrations were 207.5, 830 and 2075 mg/m3 (about 50; 200 and 500 ppm. A concurrent control group was exposed to clean air. On exposure days clinical examination was performed before, during and after exposure. During preflow period and on post exposure day clinical findings were recorded once each working day. Additionally the general state of health was controlled twice on workdays and once on weekends or holidays. Body weight of the animals was determined weekly. Ophthalmology was carried out prior to and at the end of exposure period. Detailed clinical examinations (open field observa-tion; OFO) were performed before start of exposure period and three times during exposure pe-riod in about weekly intervals. Neurofunctional tests comprising functional observational battery and motor activity measurements were performed at the end of exposure period. Hematological and clinicochemical examination of numerous parameters as well as urinalysis was performed at the end of the study as required by the corresponding test guidelines. A complete necropsy in-cluding weighing of selected organs and gross pathological evaluation was performed. Several organs and tissues were examined histopathologically as required by the corresponding test guidelines (OECD - Guideline method 412 with scope of examinations according to OECD - Guideline 407 and parts of 413).
The following study means of concentrations were determined analytically using gravimetry: 209.1 ± 12.3 (50.4); 809.0 ± 22.4 (195); 2011 ± 65.3 (485) mg/m3 (ppm).
The following substance related effects were produced by inhalation of the test substance:
Test group 3 (2075 mg/m3 (500ppm)): Low arousal during exposure, (multi)focal hyperplasia of the transitional epithelium in level I of the nasal cavity, (multi)focal degeneration of the olfactory epithelium in levels II and III of the nasal cavity, (multi)focal inflammatory cell infiltration in levels I and II of the nasal cavity
Test group 2 (830 mg/m3 (200 ppm)): (multi)focal inflammatory cell infiltration in level I of the nasal cavity
Test group 1 (207.5 mg/m3 (50ppm)): (multi)focal inflammatory cell infiltration in level I of the nasal cavity
Inhalation exposure of Wistar rats to 2075 mg/m3 (500 ppm) of the test substance vapours re-sulted in clear upper respiratory tract irritation as demonstrated by the presence of epithelial hy-perplasia or degeneration. The finding of inflammatory cell infiltration in the mid and low con-centration are also interpreted as mild reaction to the irritant properties of the inhaled vapours. No signs of systemic toxicity occurred at any concentration.
Thus the No Observed Adverse Effect Concentration (NOAEC) for systemic toxicity under the condition of this study was 2075 mg/m3 (500 ppm). The NOAEC for hyperplasia of nasal transitional and degeneration of olfactory epithelium was 830 mg/m3 (200 ppm). A NOAEC for slight irritancy leading to nasal epithelial inflammatory cell infiltration in some of the animals could not be established [cited in a modified form from BG Chemie, Toxicological Evaluation No 262, Isopropenyl acetate, CAS No 108-22-5, Berufsgenossenschaft der chemischen Industrie, 2005].
.
.
Repeated dose toxicity: inhalation - systemic effects (target organ) respiratory: other
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.